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Available online 10 April 2009The majority of human tumors are angiogenesis dependent. Understanding the specific
mechanisms that contribute to angiogenesis may offer the best approach to develop therapies
to inhibit angiogenesis in cancer. Endothelial monocyte activating polypeptide-II (EMAP-II) is an
anti-angiogenic cytokine with potent effects on endothelial cells (ECs). It inhibits EC proliferation
and cord formation, and it suppresses primary and metastatic tumor growth in-vivo. However,
very little is known about the molecular mechanisms behind the anti-angiogenic activity of EMAP-
II. In the present study, we explored the molecular mechanism behind the anti-angiogenic activity
exerted by this protein on ECs. Our results demonstrate that EMAP-II binds to the cell surface α5β1
integrin receptor. The cell surface binding of EMAP-II results in its internalization into the
cytoplasmic compartment where it interacts with its cytoplasmic partner PSMA7, a component of
the proteasome degradation pathway. This interaction increases hypoxia-inducible factor 1-alpha
(HIF-1α) degradation under hypoxic conditions. The degradation results in the inhibition of HIF-
1αmediated transcriptional activity as well as HIF-1αmediated angiogenic sprouting of ECs. HIF-
1α plays a critical role in angiogenesis by activating a variety of angiogenic growth factors. Our
results suggest that one of the major anti-angiogenic functions of EMAP-II is exerted through its
inhibition of the HIF-1α activities.
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Angiogenesis, the growth of new blood vessels, is essential for
pathological processes such as tumor growth and metastasis,
proliferative retinopathies, age-related macular degeneration, and. Libutti).
lsevier Inc.rheumatoid arthritis [1]. Endothelial cells (ECs) play a key role in
all aspects of angiogenesis [2]. Understanding specific mechanisms
that contribute to angiogenesis offer the best approach to develop
therapies to inhibit angiogenesis in cancer and other related
diseases.
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structure and has been shown to be a potent stimulus of
angiogenesis. It regulates genes that are involved in angiogenesis,
vasculogenesis, glucose metabolism and apoptosis [3]. An impor-
tant master regulator of angiogenesis under hypoxic conditions is
hypoxia-inducible factor-1 (HIF-1), a dimeric transcription factor
composed of HIF-1α and HIF-1β [4]. HIF-1α controls critical pro-
angiogenic growth factors such as vascular endothelial growth
factor (VEGF), VEGF-receptor, and erythropoietin [3–5]. Hypoxic
stabilization of HIF-1α resulting in chemo- and radio-resistance is
a hallmark of the majority of solid tumors [6]. The identification of
the molecular mechanism of HIF-1α regulation has several
implications regarding the potential treatment of several diseases.
Endothelial monocyte activating polypeptide-II (EMAP-II) is a
pro-inflammatory cytokine with potent effects on ECs. It induces
tissue factor (TF) expression to modulate coagulant responses,
induces the expression of P- and E-selectin and upregulates tumor
necrosis factor-α (TNF-α) receptors [7–9]. It inhibits EC prolifera-
tion, migration, angiogenic cord formation and induces apoptosis
[10]. EMAP-II treatment induces a TNF-like thrombohemorrhage
and renders TNF-α resistant tumors sensitive to systemic TNF-α
therapy [7,11,12]. Upregulation of EMAP-II directly after isolated
limb perfusion (ILP) of melanoma patients predicts a complete
response to TNF-α, suggesting that the EMAP-II is critical for the
antitumor activity of TNF-α [13]. The effects are thought to be the
result of EMAP-II's activity on ECs.
The various effects of EMAP-II on ECs suggest an important role
for EMAP-II in regulating tumor vasculature. However, there are
fewpublishedpapers describing themechanismof EMAP-II activity
on ECs. The present study sheds light on one of the important
mechanisms behind the anti-angiogenic activity of EMAP-II.Materials and methods
Cell culture
Human umbilical vein endothelial cells (HUVEC) were obtained
from Cambrex (New Jersey) and cultured in Endothelial Cell
Growth Medium-2 as described earlier [14]. All experiments were
conducted with HUVEC in passage 3. Human 293 cells were grown
in Dulbecco's modified eagle medium with 10% serum, 2 mM
glutamine,100 U/ml penicillin,100 μg/ml streptomycin,100 μg/ml
gentamicin and fungizome.
DNA constructs
TheHIF-1α expressionplasmid, pFLAG3HIF-1αwas a kind gift from
Dr. Gregg Semenza (the Johns Hopkins Institute for Cell Engineer-
ing) [15]. A plasmid encoding mature EMAP-II (pAAVEMAP-II) was
constructed by amplifying mature EMAP-II from plasmid pET-20b-
EMAP-II using primers with NotI and HindIII sites at 5′ and 3′,
respectively. The resulting PCR product was subcloned into an
adeno associated virus 5 backbone. The pAAV-GFP plasmid
constructed in a similar way was used as a control DNA.
Purification of EMAP-II protein
DH5α cells transformed with the pET-20b plasmid, expressing
mature EMAP-II as a histidine tagged protein were obtained fromPaul Schimmel (the Scripps Research Institute, La Jolla, CA). EMAP-
II protein was purified as described earlier [14].
Biotinylation of proteins
Biotin labeling was performed by incubating EMAP-II or bovine
serum albumin (BSA) with 10 mM solution of EZ-Link Sulfo-NHS-
Biotin (Pierce, Illinois) for 2 h on ice. The unlabeled biotin was
removed by passing the mixture through Microcon YM-10 filter
units (Millipore, Billerica, Massachusetts).
Flow cytometry
1×105 HUVEC were incubated with 0.5 μg of biotinylated EMAP-II
for various time points and the binding was detected using Avidin-
FITC by flow cytometry. Avidin-FITC reagent, biotinylated bovine
serum albumin (BSA) and an isotype control antibody were used
as controls. In the competition inhibition experiment, in addition
to biotinylated EMAP-II, cells were incubated with either non-
biotinylated EMAP-II or anti-α5β1 antibody (Clone JBS5, Millipore,
Billerica, Massachusetts) at various concentrations; 0.1 μg, 1 μg and
10 μg.
Immunofluorescence analysis
The EMAP-II binding to EC surface was examined as described by
Chang et al. [16]. Briefly, 1×106 cells were incubated with 5.0 μg of
either biotinylated EMAP-II or BSA for 1 h. In the competition
inhibition experiment, in addition to biotinylated EMAP-II, cells
were incubated with non-biotinylated EMAP-II at various concen-
trations; 10 μg and 75 μg. The binding was visualized using Avidin-
FITC (Pierce, Illinois). The nuclei were stained using 300 mM DAPI
for 2 min, followed by visualization under Zeiss Axiovert S100
fluorescent microscope (Carl Zeiss Inc. Germany).
Cell fractionation
3–5×106 HUVEC were treated with EMAP-II (0.5 μg for 1×105
cells) for different time points. After incubation, cells were
fractionated to collect different cellular fractions using ProteoEx-
tract subcellular proteome extraction kit (Calbiochem, California)
using the manufacturer's protocol. The fractions were concen-
trated by passing through Microcon YM-10 filter units and
quantitated. 30 μg of each fraction was loaded and subjected to
western analysis. In the internalization inhibition experiment, cells
were preincubated with either an isotype control antibody, anti-
α5β1 (Clone JBS5) or control β1 antibody (Clone LM534)
(Millipore, Billerica, Massachusetts) before incubating with
EMAP-II.
Western analysis
Total cell lysates were prepared from 293 or HUVEC cells using the
lysis buffer (50 mM Tris pH 7.4, 140 mM NaCl, 0.1% SDS, 1% NP40
and 0.5% sodium deoxycholate) containing protease inhibitor
cocktail (Roche, Indianapolis). The amount of protein was
quantitated using Protein assay reagent from BioRad (BioRad,
California). 20 to 30 μg of either a cellular fraction or total lysate
electrophoresed on 4–12% Bis-Tris gel (Invitrogen, Carlsbad,
California) was transferred to a nitrocellulose membrane and
blocked with 5% non-fat milk powder in PBS containing 0.1%
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antibody, followed by a secondary antibody and developed using
ECL plus (Amersham, UK). The primary antibodies used were
EMAP-II (PeproTech, New Jersey), HIF-1α (BD Biosciences), PSMA7
(BioMol, Pennsylvania), GAPDH, α5β1, α5, and β1 (Millipore,
Billerica, Massachusetts) and pan-Cadherin and Histone B (abcam,
Cambridge, Massachusetts). The secondary antibodies used were
antimouse-horseradish peroxidase (HRP) (Amersham), anti-
mouse-alkaline phosphatase (Rockland, Gilbertsville) or anti-
goat-HRP (Jackson Laboratories, Maine). Primary antibodies were
used at 1:1000 dilutions and secondary antibodies at 1:10,000
dilutions.
Pull down analysis
50 μg of the total cell lysate was incubated with different amounts
of purified EMAP-II for 1.5 h at 4 °C. The EMAP-II has a histidine tag
at the C-terminus. Thus, bound complexes were pulled down by
incubating reactions with 25 μl Ni NTA Superflow beads (Qiagen,
Valencia, CA) for 1.5 h at 4 °C. The bound proteins were eluted in
NuPAGE LDS sample buffer (Invitrogen, Carlsbad, CA) and
immunoblotted.
Peptide competition assay
The following peptides were synthesized (Sigma Genosys, the
Woodlands, Texas). Test peptides (spots 41, 42 and 45): spot 41:
PLACSPLAAG, spot 42: CSPLAAGQSR, and spot 45: RLRHGGSCHV.
Control peptides (spots 3 and 50): spot 3: ITVFSPDGHL and spot
50: AEQWAQAVWH. For the peptide competition assay, a mixture
of EMAP-II and HUVEC total cell lysate was incubated with either a
cocktail of test peptides or control peptides, followed by a pull
down analysis as described.
Transfection assays
293 cells were transfected using lipofectamine 2000 (Invitrogen,
Carlsbad, California) with pFLAG3HIF-1α (50 ng) and various
combinations of pAAVEMAP-II DNA or control DNA (10 ng, 50 ng
and 100 ng) for 24 h. In dual luciferase reporter assay, cells were
additionally transfected with 20 ng of pGL2-TK-HRE [17] and 5 ng
of Renilla plasmid (Promega, Inc., Madison, WI). In proteasome
inhibition experiments, cells were incubated with 20 μM of
proteasome inhibitor, MG132 (Calbiochem, Gibbstown, NJ) after
4 h of transfection. After a 24 h transfection, cell lysates were
prepared using NP40 lysis buffer (20 mM Tris pH 7.5, 1 mM EDTA,
137 mM NaCl, 10% glycerol and 1% NP40). The amount of protein
was quantitated and 10 μg of total lysates were subjected to
western analysis.
EC transient transfection and luciferase assay
HUVECwere electroporated using an Amaxa Nucleofector (Amaxa,
Gaithersburg, Maryland). Briefly, for optimal transfection 1×105
cells were suspended in 100 μl solution V in the presence of 1 μg of
pGL2-TK-HRE and subjected to electroporation. After 24 h, medium
was changed before treatment under hypoxic condition in hypoxic
work station. Luciferase reporter assays were performed in 96-well
optiplates (Packard Instrument, Inc., Meriden, CT) using Bright Glo
luciferase assay reagents (Promega, Inc., Madison, WI).siRNA transfection
293 cells were transfected with 50 nM control siRNA or PSMA7
Smart pool siRNA (Dharmacon, Chicago) according to the
manufacturer's protocol using DharmaFECT 1 transfection reagent.
After 48 h of transfection, total cell lysates were prepared using
NP40 lysis buffer.
The PSMA7 smart pool siRNA is a combination of 4 siRNA's and
the sequence of each duplex is given below:
Duplex 1, sense: GAAGUAUGUUGCUGAAAUUUU
Antisense: 5′-P.AAUUUCAGCAACAUACUUCUU
Duplex 2, sense: GAAGAGACAUUGUUGUUCUUU
Antisense: 5′-P.AGAACAACAAUGUCUCUUCUU
Duplex 3, sense: GAAGAUCUGUGCUUUGGAUUU
Antisense: 5′-P.AUCCAAAGCACAGAUCUUCUU
Duplex 4, sense: CAUCGUGGGUUUCGACUUUUU
Antisense: 5′-P.AAAGUCGAAACCCACGAUGUU.
Hypoxic treatment
Experiments under hypoxic conditions (1% O2) were performed in
the hypoxic workstation Invivo2 400 (Biotrace International,
Cincinnati, OH). In treatment experiments, cells were treated
with EMAP-II (0.5 μg and 1.0 μg), proteasome inhibitor MG132
(20 μM) and prolyl hydroxylase inhibitor DMOG (1 mM) (BioMol,
Pennsylvania).
Matrigel angiogenesis assay
All the experiments were performed using growth factor-reduced
Matrigel at a concentration of 1 mg/ml (BD Biosciences, Franklin
Lakes, NJ), as described [18]. HUVECs (2×104 cells per well) were
added to the Matrigel-coated plates in a final volume of 200 μl.
EMAP-II was added as indicated, and cells were then incubated
under hypoxic or normoxic conditions. 16 h later, pictures of each
well were taken using a Leica DM IRB inverted microscope
equipped with a 40×/0.55 N-PLAN objective lens (Leica, Rockville,
MD); pictures were taken with an Olympus DP70 camera
(Olympus, Melville, NY) and processed with Bioquant Image
Analysis SystemBQNOVAPRIME, version 6.75.10 (R&MBiometrics,
Nashville, TN). The effect of each treatment was also assessed by
measuring the length of cords and the number of junctions formed
using the Bioquant Image Analysis System (R&M Biometrics).Results
EMAP-II binds to ECs through integrin α5β1
HUVECwere incubated with biotinylated EMAP-II and binding was
detected using Avidin-FITC by flow cytometry under the non-
permeabilized condition (Fig. 1). The background staining by
Avidin-FITC and biotinylated BSA is shown (Fig. 1). HUVEC were
incubated with EMAP-II and binding was observed at various time
points. We observed maximum binding of EMAP-II at 5 min. With
increasing incubation time, we observed decreasing cell surface
binding by EMAP-II (Fig.1a). However, binding by biotinylated BSA,
the control protein, did not changewith increasing incubation time
(data not shown). Further, the specificity of binding was examined
Fig. 2 – EMAP-II internalization in endothelial cells. 1×106
HUVEC cells were incubated with 5 μg of biotinylated EMAP-II
(B-E) alone (b) or in combination of B-E (5 μg) and
non-biotinylated EMAP-II (E); 10 μg (c) and 75 μg (d). The cells
were stained with FITC and visualized under immunofluorescent
microscope (400×). Biotinylated BSA was used as a control (a).
The nuclei were stained blue with DAPI.
Fig. 1 – EMAP-II binding to endothelial cells. 1×105 HUVEC were
incubated with 0.5 μg of biotinylated EMAP-II (B-E) for various
time points (a) or for 30 min (b and c) and the binding was
detected using Avidin-FITC (FITC) by flow cytometry. FITC,
biotinylated BSA (B-BSA) and isotype control (IC) antibody
were used as controls. In addition to 0.5 μg of B-E, increasing
concentrations (0.1 μg, 1.0 μg and 10 μg) of either
non-biotinylated EMAP-II (E) (b) or anti-α5β1 (Ab) (c) was
added, followed by flow cytometry. The percent binding is
shown in the parentheses.
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non-biotinylated EMAP-II (Fig. 1b). Non-biotinylated EMAP-II
inhibited binding by biotinylated EMAP-II in a concentration
dependent manner (Fig. 1b). It has been shown that EMAP-II
binds to integrinα5β1 onEC surface [19].We also observed binding
between the two recombinant proteins, EMAP-II and integrinα5β1
(data not shown). In order to confirm that EMAP-II was binding to
cell surface integrin α5β1, the binding experiment was carried out
in the presence of anti-α5β1 antibody. Compared to isotype control
antibody, anti-α5β1 antibody inhibited EMAP-II binding to EC
surface in a concentration dependent manner (Fig. 1c). The results
indicate that EMAP-II binds to EC surface via integrin α5β1.
Cytoplasmic localization of EMAP-II
In order to determine the cellular fate of cell surface bound EMAP-
II, HUVEC were incubated with biotinylated EMAP-II and its
presence was detected with Avidin-FITC using an immunofluores-
cence analysis (Fig. 2). HUVEC treated with biotinylated EMAP-II
showed the presence of EMAP-II in the cytoplasm (Fig. 2b). Using
biotinylated EMAP-II, we were able to exclude the possibility that
the accumulation of EMAP-II in the cytoplasm was due to
endogenous EMAP-II. Furthermore, the internalization of biotiny-
lated EMAP-II was specific, as internalization was inhibited bythe presence of excess non-biotinylated EMAP-II (Figs. 2c, d).
Biotinylated BSA was used as a control (Fig. 2a).
To confirm cytoplasmic localization of EMAP-II in ECs, we
incubated EC with EMAP-II and analyzed different endothelial
cellular fractions (Fig. 3a). On immunoblotting with an EMAP-II
specific antibody, we observed that EMAP-II started accumulating
in the cytoplasmic compartment as early as 15 min following
incubation (Fig. 3a). There was an increase in the cytoplasmic
accumulation of EMAP-II over time, with the maximum accumula-
tion observed at 1 h, and subsequent decrease at the 2 h time point
(Fig. 3a). This observation, combined with the timing of cell
surface binding of EMAP-II, indicates that EMAP-II binds to the EC
surface and is followed by its cytoplasmic internalization.
A small fraction of EMAP-II was detected in the nuclear
fractions. We confirmed a complete cellular fractionation proce-
dure and an equal loading by reprobing the same blot with GAPDH
(cytoplasmic marker), Cadherin (membrane marker) and histone
B (nuclear marker) antibodies (Fig. 3a). Further, we examined the
effect of EMAP-II binding to integrin α5β1 on the EC surface to
discern EMAP-II's ability to internalize into cytoplasmic compart-
ment of EC. The preincubation of ECs with either an isotype control
antibody or non-neutralizing integrin β1 antibody did not affect
cytoplasmic accumulation of EMAP-II (Fig. 3b). However, pre-
incubation of ECs with anti-α5β1 antibody inhibited EMAP-II
internalization into the cytoplasmic compartment in a dose
dependent manner (Fig. 3b). The observed inhibition of EMAP-II
internalization may be because of decreased cell surface binding of
EMAP-II in the presence of anti-α5β1 antibody.
EMAP-II binds to PSMA7, a component of the proteasome
degradation pathway
Next, we focused our studies on the cytoplasmic localization of
EMAP-II. In order to identify proteins thatmay interact with EMAP-
Fig. 4 – EMAP-II binds to PSMA7 protein. (a) The total cell lysate
from HUVEC were incubated with different amounts of
histidine tagged EMAP-II protein. Following this, nickel agarose
beads were added and the EMAP-II bound proteins were pulled
down. The bound complexeswere immunoblotted using PSMA7
specific antibody. (b) EMAP-II (500 ng) was preincubated either
with a cocktail of test peptides (lanes 3 and 4, 1 μM and 10 μM,
respectively) or a cocktail of control peptides (lanes 5 and 6,
1 μM and 10 μM, respectively). After incubation with peptides,
HUVEC lysate was added followed by the addition of nickel
agarose beads. The EMAP-II bound proteins were separated and
immunoblotted using PSMA7 specific antibody.
Fig. 3 – Cellular localization of EMAP-II. (a) HUVEC were
incubated with EMAP-II for different time points. Cells were
fractionated to obtain cytoplasmic, membrane and nuclear
fractions and immunoblotted with EMAP-II specific antibody.
GAPDH, Cadherin and histone B blotting indicate cytoplasmic,
membrane and nuclear fractionation controls and equal
loading. (b) HUVEC were incubated either with an isotype
control antibody (10 μg) or anti-α5β1 antibody or with anti-β1
antibody for 30min before incubating with EMAP-II for 15min.
Cells were fractionated to obtain cytoplasmic fraction and
immunoblotted with EMAP-II specific antibody.
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(Supplementary Fig. 1). On the yeast two-hybrid screen, we
identified a component of human proteasome subunit, alpha
type, 7 (PSMA7) (accession number NM_002792) as a binding
partner to EMAP-II.
We confirmed the direct interaction between EMAP-II and
PSMA7 using a pull down analysis (Fig. 4a). In the absence of
EMAP-II, minimum amounts of PSMA7 was pulled down from the
EC lysate; however, addition of increasing amounts of EMAP-II to
the reaction pulled down increasing amounts of PSMA7 from the
total EC lysate in a concentration dependent manner (Fig. 4a).
EMAP-II could pull down PSMA7 from EC lysate indicating binding
between the two proteins and confirming the yeast two-hybrid
data.
In order to examine which region of PSMA7 is involved in
binding with EMAP-II, we used a PSMA7 peptide spot array
(Supplementary Fig. 2). Using this approach, we identified two
putative regions of PSMA7 (spotted as, spots 41, 42 and 45) that
bound to EMAP-II (Supplementary Fig. 2a). Deduced from the spot
location, the binding sites were, PLACSPLAAGQSR and
RLRHGGSCHV. The background binding is shown (Supplementary
Fig. 2b). To provide further confirmation of this binding at a
molecular level, we examined the ability of EMAP-II to pull down
PSMA7 from EC lysate in the presence of a cocktail of purified
binding peptides (Fig. 4b). We synthesized three peptides (test
peptides) which bound to EMAP-II on the spot array (spots 41, 42
and 45) and two peptides (control peptides) which did not bind to
EMAP-II on the spot array analysis (spots 3 and 50). In the absence
of test peptides, EMAP-II could pull down PSMA7 from EC (Fig. 4b,
lane 2). However, a cocktail of three test peptides, (41, 42 and 45)
inhibited the amount of PSMA7 pulled down by EMAP-II in a
concentration dependent manner (Fig. 4b, lanes 3 and 4). At the
same tested concentrations, a mixture of control peptides, (3 and50) did not inhibit PSMA7 pulled down by EMAP-II (Fig. 4b, lanes 5
and 6).
EMAP-II degrades HIF-1α and inhibits the transcriptional
activity of HIF-1α through a proteasome-dependent pathway
via PSMA7
It has previously been shown that PSMA7 mediates HIF-1α
degradation and inhibits its transactivation activity [20]. In the
current study, we have demonstrated that EMAP-II binds to
PSMA7. In order to determine the biological significance of
PSMA7 interaction with EMAP-II, we studied the role of EMAP-II
in PSMA7 mediated HIF-1α degradation. In 293 cells, we
exogenously overexpressed HIF-α and EMAP-II (Fig. 5). 293 cells
express endogenous PSMA7 (data not shown). We achieved about
80% transfection efficiency in these experiments as demonstrated
by the control plasmid, pAAV-GFP (data not shown). The
experiments were repeated three times. We observed good levels
of HIF-1α expression (Fig. 5a, lane 1). However, on co-transfection
with EMAP-II, we observed low levels of HIF-1αwhen compared to
the control (Fig. 5a, lanes 2–4 compared to lanes 5–7). The effect of
EMAP-II on HIF-1α levels was concentration dependent.
Further, we studied the effect of EMAP-II on the transcriptional
activity of HIF-1α in a dual luciferase reporter assay system (Fig. 5b).
The transfection of HIF-1α increased the expression of the reporter
gene by 7-fold over the basal level. However, on co-transfection,
EMAP-II significantly inhibited HIF-1α mediated transcriptional
activity when compared to the control (Fig. 5b). Thus, EMAP-II
modulated HIF-1α function at the transcriptional level.
It has been shown that HIF-1α degradation occurs via the
proteasomedegradationpathway through its binding to PSMA7 [20].
To examinewhether EMAP-II plays any role in proteasomemediated
HIF-1α degradation, we used a broad range proteasome inhibitor,
MG132, and accessed HIF-1α levels in 293 cells (Supplementary
Fig. 3). In the presence of MG132, EMAP-II did not affect HIF-1α
levels (Supplementary Fig. 3). Thedata indicates that EMAP-II plays a
role in proteasome mediated HIF-1α degradation.
Fig. 6 – EMAP-II mediates HIF-1α degradation and inhibition of
its transcriptional activity via PSMA7. 293 cells were transfected
with 50 nM PSMA7 specific siRNA or control siRNA for 48 h.
After that, cells were transfected with pFLAG3HIF-1α (50 ng)
and various combinations of pAAVEMAP-II DNA or control DNA
(10 ng, 50 ng and 100 ng) for 24 h. In dual luciferase reporter
assay, cells were additionally transfected with 20 ng of
pGL2-TK-HRE and 5 ng of Renilla plasmid. (a) Whole cell lysates
were prepared and immunoblotted with specific antibody to
HIF-1α. GAPDH protein levels show equal loading. (b) After 24 h
of transfection, luciferase reporter assays were performed
using dual luciferase assay system. Scale bars=standard
deviation. The luciferase activity is represented as a ratio of
expression levels of luciferase/renilla.
Fig. 5 – EMAP-II regulates HIF-1α protein levels and inhibits
HIF-1αmediated transcriptional activity. 293 cells transfected
with pFLAG3HIF-1α (50 ng) and various combinations of
pAAVEMAP-II DNA or control DNA (10 ng, 50 ng and 100 ng) for
24 h. In dual luciferase reporter assay, cells were additionally
transfected with 20 ng of pGL2-TK-HRE and 5 ng of Renilla
plasmid. (a)Whole cell lysateswerepreparedand immunoblotted
withspecific antibody toHIF-1α. GAPDHprotein levels showequal
loading. (b) After 24 h of transfection, luciferase reporter assays
were performed using dual luciferase assay system. Scale
bars=standarddeviation. The luciferase activity is represented as
a ratio of expression levels of luciferase/renilla.
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in EMAP-II mediated HIF-1α degradation, we downregulated
PSMA7 in 293 cells using siRNA and then overexpressed HIF-1α
and EMAP-II/control DNA (Fig. 6). The PSMA7 siRNA used was
specific and effective in downregulating PSMA7 (Supplementary
Fig. 4). As observed before, EMAP-II inhibited HIF-1α protein levels
in control siRNA transfected cells (Fig. 6a, lanes 2 and 3 compared
to lanes 4 and 5). In contrast, in cells with downregulated PSMA7,
EMAP-II failed to degrade HIF-1α (Fig. 6a, lanes 7 and 8). This
experiment was repeated three times.
We observed a similar effect of PSMA7 downregulation and
EMAP-II on HIF-1α mediated transcriptional activity (Fig. 6b). In
the presence of PSMA7 (control siRNA), EMAP-II inhibited HIF-1α
mediated transcriptional activity of the reporter gene whereas
downregulation of PSMA7 abrogated the ability of EMAP-II to
inhibit reporter gene expression (Fig. 6b).
Thus, the data indicate that PSMA7 is required for both EMAP-II
mediated HIF-1α degradation and inhibition of its transcriptional
activity.
EMAP-II degrades HIF-1α and inhibits its transcriptional
activity via the proteasome degradation pathway in ECs
Further, we examined whether EMAP-II mediated HIF-1α degra-
dation and inhibition of its transcriptional activity occurs under
physiological conditions in ECs. ECs were grown under normoxic/
hypoxic conditions and were treated with EMAP-II (Fig. 7). Asexpected, we did not observe induction of HIF-1α under normoxic
conditions (Fig. 7a, lane 1). In contrast, under hypoxic conditions,
there was an increase in HIF-1α protein levels (Fig. 7a, lane 2).
However, HIF-1α protein levels were decreased following EMAP-II
treatment under hypoxic conditions at both tested concentrations
(Fig. 7a, lanes 3 and 4). Thus, EMAP-II could decrease HIF-1α
protein levels in ECs under physiologic conditions in a manner
similar to what was observed in 293 cells. Further, we studied the
role of the proteasome in HIF-1α degradation after EMAP-II
treatment of ECs. ECs are difficult to transfect and also show
greater variability in transfection efficiency. Hence, instead of using
siRNA to downregulate PSMA7, we used a broad range proteasome
inhibitor, MG132, in order to obtain more consistent results in
these studies. In the presence of MG132, EMAP-II failed to inhibit
HIF-1α protein levels indicating that EMAP-II degrades HIF-1α via
a proteasome-dependent degradation pathway in ECs (Fig. 7a,
lanes 5 and 6). However, under hypoxic conditions, inhibition of
the proteasome further stabilized HIF-1α levels (Fig. 7a, lanes 5–7
compared to lane 2). This can be attributed to the broad range of
proteasome inhibition by MG132. The results also indicate that
there are EMAP-II independent mechanisms involved in the
degradation of HIF-1α under hypoxic conditions. Furthermore,
we examined whether EMAP-II mediates HIF-1α degradation via a
well studied VHL degradation pathway. We inhibited the VHL
Fig. 7 – EMAP-II mediates HIF-1α degradation and inhibition of
HIF-1α transcriptional activity via the proteasome degradation
pathway in endothelial cells. (a) HUVEC were grown either
under normoxia (20% oxygen) (lanes 1) or hypoxia (1% oxygen)
(lanes 2–10) and treated with EMAP-II, MG132 (20 μM) and
DMOG (1 mM) as indicated. The lysates were prepared and
immunoblotted against HIF-1α antibody. The GAPDH control
shows equal loading. (b) HUVEC were electroporated with 1 μg
of pGL2-TK-HRE DNA using an Amaxa Nucleofector. After 24 h,
cells were treated with 20 μMMG132 (MG) and EMAP-II as
indicated and grown either under normoxic (Nor) (20% oxygen)
or hypoxic (Hyp) (1% oxygen) conditions. Luciferase reporter
assays were performed in 96-well optiplates using Bright Glo
luciferase assay reagents. Scale bars=standard deviation.
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xylase inhibitor, DMOG. In the presence of DMOG, EMAP-II could
not degrade HIF-1α (Fig. 7a, lanes 8 and 9). The data suggest that
EMAP-II might be one of the players in the multicomponent VHL
proteasomal degradation pathway involving HIF-1α degradation.
However, DMOG could stabilize HIF-1α in the absence of EMAP-II
indicating that there are EMAP-II independent VHL proteasomal
degradation pathways (Fig. 7a, lane 10).
Next, we examined the role of EMAP-II in the transactivation
function of HIF-1α in ECs using a luciferase reporter assay system
(Fig. 7b). Compared to normoxia, we observed a significant increase
in luciferase activity under hypoxic conditions indicating HIF-1α
mediated transactivation of the reporter gene. The HIF-1αmediated
transactivation was inhibited following treatment with EMAP-II
(Fig. 7b). However, the EMAP-II mediated inhibition of transcription
was abolished by treatment with MG132 (Fig. 7b). The results
suggest that in ECs, EMAP-II inhibits HIF-1α transactivation by
regulating HIF-1α levels via a proteasomal degradation pathway.
EMAP-II inhibits EC cord formation under hypoxic conditions
To examine the physiological significance of the regulation of HIF-
1α activity by EMAP-II, we analyzed angiogenic cord formation inECs, one of the important functions of HIF-1α. ECs cultured under
hypoxic conditions in growth factor depleted medium form tube
like structures in contrast to cells growing under normoxic
conditions (Figs. 8, a and b). The EC cord formationwas completely
inhibited by EMAP-II treatment under hypoxic conditions (Figs. 8, c
and d). However, the effect of EMAP-II on cord formation was
abolished by treatment withMG132 (Figs. 8, e and f). The length of
the cords and the number of cord junctions were measured and
quantitated (Figs. 8, g and h). Cells grown under hypoxia showed
longer cords compared to cells treated with EMAP-II (Fig. 8g). The
effect of EMAP-II on cord length was abolished in the presence of
MG132 under hypoxic conditions. A similar pattern was observed
with the number of cord junctions in each treatment group
(Fig. 8h). The data indicate that EMAP-II inhibits angiogenic cord
formation via regulation of HIF-1α activity in ECs.Discussion
The regulation of angiogenesis by hypoxia is an important
component of normal vascular homeostasis [21,22]. Under patho-
logical conditions such as cancer, hypoxia results in the upregula-
tion of the angiogenesis-stimulating factor HIF-1α. HIF-1α induces
angiogenesis which is critical for tumor cell proliferation and
survival [22]. Under similar conditions, various cell types (mono-
cytes, macrophages and tumor cells) secret EMAP-II, a multi-
functional cytokine cleaved from its precursor Pro-EMAP. EMAP-II
has been shown to have anti-angiogenic properties including
the inhibition of EC proliferation, tube formation, adhesion to
fibronectin and induction of EC apoptosis [8,19] (Fig. 9). In the
present series of studies, we explored how EMAP-II exerts some of
its anti-angiogenic activities on ECs. Our results indicate that
EMAP-II regulates HIF-1α activity, resulting in the inhibition of
angiogenic cord formation in ECs. This is depicted schematically in
Fig. 9.
To gain an insight into the mechanism of anti-angiogenic
activity of EMAP-II, we carried out a series of investigations to
elucidate the fate of cell surface bound EMAP-II. We studied the
downstream biochemical and molecular effects of EMAP-II on ECs.
It has been shown that EMAP-II binds to different EC surface
molecules to exert some of its activities. EMAP-II inhibits EC
proliferation by binding to ATP synthase whereas it inhibits EC
adhesion and spreading via direct binding to integrinα5β1 (Fig. 9)
[16,19]. In the present study, we confirmed EMAP-II binding to
integrin α5β1 on ECs. Cell surface integrin receptors play an
important role in regulating vascular growth [23]. The anti-
angiogenic proteins endostatin and tumstatin exert their effects
through α5β1 and αvβ3 receptors, respectively [24,25]. Our data
showed that after binding to the cell surface of ECs, the majority of
EMAP-II was internalized into the cytoplasmic compartment.
Although, we also observed low levels of EMAP-II in the nucleus,
in the present study we focused on the role of cytoplasmic EMAP-
II. Preincubation of ECs with anti-α5β1 antibody inhibited EMAP-II
cell surface binding and subsequent internalization into the
cytoplasm indicating that α5β1 is the cell surface binding receptor
for EMAP-II on ECs. However, it is possible that integrin α5β1 may
also play a role in the internalization process of EMAP-II. It has
been demonstrated that β1 integrins, including α5β1, play an
important role in endocytosis and turnover of the extracellular
matrix component fibronectin via caveolin-1 [26,27].
Fig. 8 – EMAP-II inhibits HIF-1α induced cord formation. HUVEC were plated onto the growth factor-reduced Matrigel-coated plates
(2×104 cells perwell) and 0.5 μg (c and e) and 1.0 μg (d and f) EMAP-II was added followed by 20 μMMG132 (MG) (e and f). Cells were
then incubated under normoxic (Nor) (20% oxygen) (a) or hypoxic (Hyp) (1% oxygen) (b–f) conditions. 16 h later, each well was
photographed using a Leica DM IRB invertedmicroscope equippedwith a 40×/0.55 N-PLANobjective lens andOlympus DP70 camera
(a–f). The effect of each treatment was assessed bymeasuring the length of cords (g) and the number of junctions (h) formed using
the Bioquant Image Analysis system. Scale bars=standard deviation.
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mic proteins to exert its effect, we utilized a yeast two-hybrid system.
We identified PSMA7, one of the components of the proteasome
degradation pathway as a binding partner for EMAP-II. The 26S
proteasome complex is a ubiquitous multi-catalytic protease complex
composed of the 20S catalytic core complex and the 19S regulatory
complex [28]. The polyubiquitinated protein substrates are degraded
inside the 20S core complex. PSMA7, an α-type subunit of the 20S
proteasome core complex, physically interacts with HIF-1α and
inhibits the transactivation activity of HIF-1α by causing the
proteasome-dependent degradation of HIF-1α [20]. Given the
published role of PSMA7 in HIF-1α degradation and our observation
that PSMA7 binds to EMAP-II, we next examined whether EMAP-II is
involved in HIF-1α regulation through the proteasome. Using a
proteasome inhibitor, we demonstrated that EMAP-II mediates HIF-
1α degradation via the proteasome and PSMA7 is required for this
process. Thiswas because downregulation of PSMA7 abolished EMAP-
II mediated HIF-1α degradation as well as its transactivation function.
Although PSMA7 is required for EMAP-II mediated HIF-1α regulation,
we do not know whether the physical binding between EMAP-II andPSMA7 is necessary for this process to occur. The remarkable plasticity
of HIF-1α, its importance in the vascular system, and the number of
different proteins that regulate this process indicate that there also
exist EMAP-II independent HIF-1α degradation pathways [15]. The
von Hippel–Lindau (VHL) ubiquitination degradation pathway of HIF-
1α degradation has been well elucidated [29–31]. A number of
different proteins regulate this process [15]. Our findings indicate that
EMAP-II may be a part of the multicomponent VHL-proteasome
ubiquitination pathway while there are also EMAP-II independent
VHL proteasomal degradation pathways that exist. Thus, there is a
large repertoire of different molecular pathways involved in HIF-1α
regulation. This is not surprising, given the vast diversity of genes
regulated by HIF-1α [4]. We are currently examining the exact role of
EMAP-II in the VHL-proteasome ubiquitination pathway of HIF-1α
degradation.
In the current study,wehavedemonstrated thedirect consequence
of HIF-1α degradation by EMAP-II. It has been shown that under
hypoxic conditions, ECs cultured in the absence of growth factors
survive and form tube like structures via HIF-1α expression [8,18,32].
We also know that EMAP-II inhibits angiogenesis via inhibition of
Fig. 9 – EMAP-II, a multifunctional cytokine has potent effects on endothelial cells. The molecular mechanism and the functional
consequence of EMAP-II mediated HIF-1α regulation presented in this study is depicted (black box).
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inhibits angiogenic cord formation by regulation of HIF-1α. The newly
formed angiogenic cords are the basis of angiogenesis in growing
tumors. Tumor progression is dependent on its ability to establish a
vascular network [33]. HIF-1α, an important player in tumor
angiogenesis, has been reported in a variety of human cancers [34].
A number of genes involved in the control of growth signaling, cell
survival and invasionwere found tobe induceddirectlyor indirectly by
HIF-1α [6]. HIF-1α plays a critical role in tumor angiogenesis by
activating angiogenic growth factors including VEGF and mediates a
cell-autonomous transcriptional response in human ECs [35–37].
Hypoxic cells are more resistant to ionizing radiation and chemother-
apy, are more invasive and metastatic, resistant to apoptosis, and
geneticallyunstable [38]. Thus,HIF-1α is emergingasa commontarget
underlying the different aspects of tumor progression. Our finding that
EMAP-II regulates HIF-1α activities may result in wide-ranging
applications for EMAP-II in several therapeutic regimens.Acknowledgments
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